亿胜

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021.12.20

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021.11.10

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021.10.27

Date

Title

2021-12-20

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-11-10

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-10-27

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

2021-08-12

Essex Bio-Technology Reports First Half 2021 Financial Results

2021-07-25

Essex Bio-Technology Listed on Two Authoritative Lists

2021-07-19

First Patient First Visit Completed in the PRC in Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-04-30

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2021 Annual Meeting

2021-04-20

Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT